Prognostic Value of TEL-AML1 Fusion Gene in Childhood B-ALL
Author Information
Author(s): Mosad Eman, Hamed Hosny B, Bakry Rania M, Ezz-Eldin Azza M, Khalifa Nesrine M
Primary Institution: South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Hypothesis
Does the persistence of the TEL-AML1 fusion gene as minimal residual disease have prognostic value in childhood CD 10 positive B-acute lymphoblastic leukemia?
Conclusion
The presence of the TEL-AML1 fusion gene at diagnosis suggests a favorable prognosis, but its persistence as minimal residual disease does not provide additional prognostic value.
Supporting Evidence
- TEL-AML1 fusion gene was positive in 37.5% of newly diagnosed patients.
- A significant correlation was found between TEL-AML1 fusion gene and favorable disease course.
- The mean survival time was significantly longer for patients with TEL-AML1 fusion at diagnosis compared to those without.
Takeaway
This study looked at a gene that can help doctors understand how well children with a certain type of leukemia might do. It found that while having the gene at the start is good, keeping it later doesn't help predict how well kids will do.
Methodology
Fluorescence in situ hybridization (FISH) was used to evaluate bone marrow samples from 80 patients diagnosed with CD 10 positive B-ALL.
Limitations
The study was retrospective and had a limited number of patients evaluated for minimal residual disease.
Participant Demographics
Patients aged 3 to 11 years, with a mean age of 7.4 years; 70% male and 30% female.
Statistical Information
P-Value
0.006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website